Company Description: Guidant Bio (aka Sonnet Bio) is a clinical stage oncology company with differentiated dual-cytokine and next gen ADC assets built on our clinically validated proprietary tumor-targeting delivery platform. We have spun out all the Sonnet Bio assets after a reverse merger of the publicly listed entity with a crypto company. We see pipeline value inflection milestones at 1, 2 and 3 years with a $20MM to $30MM funding. We are also looking for partnerships for co-development on our next gen ADC targeted delivery platform.Our dual IL-12+IL-15 fusion protein couples with circulating albumin to get actively transported and sequestered in the tumor microenvironment. Synergistic activity of IL12 and 15 gives 2X more potency than IL-12 or IL-15 alone. The phase I clinical data with IL-12 and this targeted delivery platform demonstrates safety at high doses , along with a regulatory pathway for IL-15 in bladder cancer makes this a low risk rapid development approach with POC in 18 mos.

Goal for Presentation: Closing out our seed financing round of $30M in order to rapidly get proof of concept in bladder cancer with our dual cytokine asset and establish multiple partnerships with our next-generation targeted delivery ADC platform.

Additional Comments:

Who referred you to this application?: